{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:19:22Z","timestamp":1790716762525,"version":"4.1.0"},"reference-count":63,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Exportin-1 (XPO1) is a key player in the nuclear export pathway and is overexpressed in almost all cancers. This is especially relevant for non-Hodgkin lymphoma (NHL), where high XPO1 expression is associated with poor prognosis due to its oncogenic role in exporting proteins and RNA that are involved in cancer progression and treatment resistance. Here, we discuss the proteins and RNA transcripts that have been identified as XPO1 cargo in NHL lymphoma including tumour suppressors, immune modulators, and transcription factors, and their implications for oncogenesis. We then highlight the research to date on XPO1 inhibitors such as selinexor and other selective inhibitors of nuclear export (SINEs), which are used to treat some cases of non-Hodgkin lymphoma. In vitro, in vivo, and clinical studies investigating the anti-cancer effects of SINEs from bench to bedside, both as a single agent and in combination, are also reported. Finally, we discuss the limitations of the current research landscape and future directions to better understand and improve the clinical utility of SINE compounds in NHL.<\/jats:p>","DOI":"10.3390\/biom13010111","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:11:51Z","timestamp":1672899111000},"page":"111","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-0625","authenticated-orcid":false,"given":"Kyla L.","family":"Trkulja","sequence":"first","affiliation":[{"name":"Institute of Medical Science, University of Toronto, 27 King\u2019s College Circle, Toronto, ON M5S 1A1, Canada"},{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farheen","family":"Manji","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Institute of Medical Science, University of Toronto, 27 King\u2019s College Circle, Toronto, ON M5S 1A1, Canada"},{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob C.","family":"Laister","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1083\/jcb.201601004","article-title":"Simple rules for passive diffusion through the nuclear pore complex","volume":"215","author":"Timney","year":"2016","journal-title":"J. Cell Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12248","DOI":"10.1038\/s41598-018-30686-1","article-title":"Anti-tumour efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumour suppressor","volume":"8","author":"Subhash","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.bbamcr.2010.10.014","article-title":"Nuclear import by karyopherin-\u03b2s: Recognition and inhibition","volume":"1813","author":"Chook","year":"2011","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Cell Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1600-0854.2005.00270.x","article-title":"Mechanisms of Receptor-Mediated Nuclear Import and Nuclear Export","volume":"6","author":"Pemberton","year":"2005","journal-title":"Traffic"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11466","DOI":"10.7554\/eLife.11466","article-title":"A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning","volume":"4","author":"Kirli","year":"2015","journal-title":"eLife"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.clml.2019.08.011","article-title":"Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies","volume":"19","author":"Allegra","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2012.074781","article-title":"Selective inhibitors of nuclear export for the treatment of non-Hodgkin\u2019s lymphomas","volume":"98","author":"Azmi","year":"2013","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IkappaB","volume":"17","author":"Ming","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cellsig.2018.02.016","article-title":"STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma","volume":"46","author":"Miloudi","year":"2018","journal-title":"Cell. Signal."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tabe, Y., Kojima, K., Yamamoto, S., Sekihara, K., Matsushita, H., Davis, R.E., Wang, Z., Ma, W., Ishizawa, J., and Kazuno, S. (2015). Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137210"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","article-title":"Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage","volume":"42","author":"Karimian","year":"2016","journal-title":"DNA Repair"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-018-0856-3","article-title":"Critical role of FOXO3a in carcinogenesis","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/cas.12430","article-title":"Induction of p53-mediated transcription and apoptosis by exportin-1 ( XPO 1) inhibition in mantle cell lymphoma","volume":"105","author":"Yoshimura","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13045-020-00982-3","article-title":"XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53","volume":"13","author":"Deng","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"30773","DOI":"10.18632\/oncotarget.25637","article-title":"Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents","volume":"9","author":"Kashyap","year":"2018","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-020-0958-y","article-title":"Targeting nuclear import and export in hematological malignancies","volume":"34","author":"Nachmias","year":"2020","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-kappaB deactivation and combines with proteasome inhibitors to synergistically induce tumour cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2147\/OTT.S161109","article-title":"Role of the NF\u03baB-signaling pathway in cancer","volume":"11","author":"Xia","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: A leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood-2014-06-582650","article-title":"Activating STAT6 mutations in follicular lymphoma","volume":"125","author":"Yildiz","year":"2015","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2009-03-209759","article-title":"Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma","volume":"114","author":"Ritz","year":"2009","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","article-title":"Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas","volume":"22","author":"Morin","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1535-7163.MCT-13-0416","article-title":"XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer","volume":"13","author":"Cheng","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Borden, K.L.B. (2020). The Nuclear Pore Complex and mRNA Export in Cancer. Cancers, 13.","DOI":"10.3390\/cancers13010042"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.celrep.2012.07.007","article-title":"The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation","volume":"2","author":"Baguet","year":"2012","journal-title":"Cell Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tcb.2013.03.006","article-title":"Postage for the messenger: Designating routes for nuclear mRNA export","volume":"23","author":"Natalizio","year":"2013","journal-title":"Trends Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3389\/fgene.2018.00512","article-title":"The Impact of Post-transcriptional Control: Better Living Through RNA Regulons","volume":"9","author":"Borden","year":"2018","journal-title":"Front. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1022943419011","article-title":"Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF4E selectively enhances translation of metastasis-related mRNAs","volume":"20","author":"Graff","year":"2003","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1083\/jcb.200501019","article-title":"eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3\u2032UTR","volume":"169","author":"Culjkovic","year":"2005","journal-title":"J. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20160271","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein\u2013Barr virus-associated lymphomas","volume":"372","author":"Rickinson","year":"2017","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tcb.2007.02.003","article-title":"CRM1-mediated nuclear export: To the pore and beyond","volume":"17","author":"Hutten","year":"2007","journal-title":"Trends Cell Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1093\/nar\/gky306","article-title":"Dicer cleaves 5\u2032-extended microRNA precursors originating from RNA polymerase II transcription start sites","volume":"46","author":"Sheng","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/genes6010124","article-title":"RNA Export through the NPC in Eukaryotes","volume":"6","author":"Okamura","year":"2015","journal-title":"Genes"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1242\/jcs.115.14.2985","article-title":"Requirements for the nuclear export of the small ribosomal subunit","volume":"115","author":"Moy","year":"2002","journal-title":"J. Cell Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.leukres.2014.10.003","article-title":"CRM1 as a new therapeutic target for non-Hodgkin lymphoma","volume":"39","author":"Han","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-019-0188-6","article-title":"The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells","volume":"9","author":"Abeykoon","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Xu, P., Liu, X., Ouyang, J., and Chen, B. (2017). TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174809"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11670-012-0278-5","article-title":"Potential effects of CRM1 inhibition in mantle cell lymphoma","volume":"24","author":"Zhang","year":"2012","journal-title":"Chin. J. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/onco.13859","article-title":"FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"26","author":"Kasamon","year":"2021","journal-title":"Oncologist"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2018.214759","article-title":"The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents","volume":"104","author":"Tarantelli","year":"2019","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1182\/blood.2020009013","article-title":"Salicylates enhance CRM1 inhibitor antitumour activity by induction of S-phase arrest and impairment of DNA-damage repair","volume":"137","author":"Abeykoon","year":"2021","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/1538-7445.AM2016-1299","article-title":"Abstract 1299: Selinexor, a selective inhibitor of nuclear export (SINE) compound shows enhanced anti-tumour activity when combined with either venetoclax or bendamustine in diffuse large B cell lymphoma (DLBCL) mouse models","volume":"76","author":"Elloul","year":"2016","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-20-4929","article-title":"Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study","volume":"27","author":"Seymour","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.2147\/OTT.S238832","article-title":"Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed\/Refractory Mantle Cell Lymphoma: Evidence to Date","volume":"13","author":"Sawalha","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1182\/bloodadvances.2020003698","article-title":"Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma","volume":"6","author":"Yang","year":"2022","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/blood.V128.22.4131.4131","article-title":"Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo","volume":"128","author":"Kashyap","year":"2016","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopha.2018.08.151","article-title":"Bortezomib inhibited the progression of diffuse large B-cell lymphoma via targeting miR-198","volume":"108","author":"Wang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1128\/MCB.25.14.5985-6004.2005","article-title":"Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis","volume":"25","author":"Stark","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","article-title":"XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIalpha to the Nucleus","volume":"22","author":"Ranganathan","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/leu.2011.378","article-title":"BCL2 mutations in diffuse large B-cell lymphoma","volume":"26","author":"Schuetz","year":"2011","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.leukres.2011.10.024","article-title":"Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain","volume":"36","author":"Medina","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","article-title":"Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies","volume":"6","author":"Hall","year":"1992","journal-title":"Blood Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hon.100_2631","article-title":"Real-World Bendamustine Use in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (R\/R DLBCL)","volume":"37","author":"Herrera","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00277-018-3317-6","article-title":"Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: A multicenter retrospective analysis","volume":"97","author":"Hong","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1038\/cddis.2013.307","article-title":"Gemcitabine-mediated tumour regression and p53-dependent gene expression: Implications for colon and pancreatic cancer therapy","volume":"4","author":"Hill","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2019-124544","article-title":"Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.3324\/haematol.2020.251454","article-title":"Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer\/T-cell lymphoma","volume":"106","author":"Tang","year":"2021","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V124.21.396.396","article-title":"The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed\/Refractory Non Hodgkin\u2019s Lymphoma (NHL)","volume":"124","author":"Kuruvilla","year":"2014","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.V128.22.463.463","article-title":"XPO1 Inhibition By Selinexor Synergizes with BCR Inhibition, Blocks Tumour Growth and Prolongs Survival in a Bioluminescent Animal Model of Primary Central Nervous System Lymphoma","volume":"128","author":"Crespo","year":"2016","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-21-3867","article-title":"Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study","volume":"28","author":"Stephens","year":"2022","journal-title":"Clin. Cancer Res."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/1\/111\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:00:08Z","timestamp":1760119208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/1\/111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["biom13010111"],"URL":"https:\/\/doi.org\/10.3390\/biom13010111","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}